Welcome to Awesome Blog Design perfect blog

Category: Business

Local, national & international business news and events.

Business, Healthcare

Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy for first-line treatment of metastatic non-small cell lung cancer

Approval based on Phase 3 CheckMate -9LA trial results showing superior overall survival in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression or tumor histologies European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is

Business

LianBio announces clearance to initiate the Phase 3 PROOF trial of Infigratinib in patients with locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions in China

SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced that it has received clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration

Business, Healthcare

Catalent, Inc. reports first quarter fiscal 2021 results

 Q1’21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1’20. On an organic basis, constant currency net revenue in Q1’21 grew 20% compared to Q1’20.  Q1’21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or

Business, Healthcare

DESTINY-Breast05 head-to-head phase 3 trial of ENHERTU® versus T-DM1 initiated in patients with HER2 positive early breast cancer at high risk after neo-adjuvant therapy

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of DESTINY-Breast05, a global phase 3, head-to-head trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki) versus ado-trastuzumab emtansine (T-DM1) as adjuvant therapy in patients with